Review: Analogies between trophoblastic and malignant cells

American Journal of Reproductive Immunology

Volumn 39, Issue 1, 1998, Pages 41-49

  Mullen, Catherine A ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Anti idiotype therapy; MHC expression; Natural killer cells; Prostaglandin E; Th2 response; Transforming growth factor beta

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; PROSTAGLANDIN E; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER CELL; CYTOLOGY; CYTOLYSIS; HELPER CELL; HUMAN; IMMUNOTHERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; TROPHOBLAST;

EID: 0031986210     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0897.1998.tb00332.x     Document Type: Review

References (79)

1. Faulk WP, Temple A: Distribution of beta-2-microlobulin and HLA in chorionic villi of human placentae. Nature 1976; 262:799-802.
2. Sunderland CA, Redman CWG, Stirrat GM: HLA-A,B,C antigens are expressed on nonvillous trophoblasts of the early human placenta. J Immunol 1981; 127:2614-2615.
3. Ellis SA, Palmer MS, McMichael AJ: Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA class I molecule. J Immunol 1990; 144:731-735.
4. Shorter SC, Starkey PM, Ferry BL, Clover LM, Sargent IL, Redman CW: Antigenic heterogeneity of human cytotrophoblast and evidence for the transient expression of MHC class I antigens distinct from HLA-G. Placenta 1993; 14:571-582.
5. Singal DP, Ye M, Qiu X: Molecular basis for lack of expression of HLA Class I antigens in human small-cell lung carcinoma cell lines. Int J Cancer 1996; 68:629-636.
6. Connor ME, Stern PL: Loss of MHC class I expression in cervical carcinomas. Int J Cancer 1990; 46:1029-1034.
7. Wadee AA, Paterson A, Coplan KA, Reddy SG: HLA expression in hepatocellar carcinoma cell lines. Clin Exp Immunol 1994; 97:328-333.
8. Smith MEF, Marsh SGE, Bodmer JG, Gelsthorpe K, Bodmer WF: Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc Natl Acad Sci USA 1989; 86:5557-5561.
9. Trowsdale J, Travers P, Bodmer WF, Patillo RA: Expression of HLA-A,B,C and beta 2-microglobulin antigens in human choriocarcinoma cell lines. J Exp Med 1980; 152:11s-17s.
10. Moller P, Herrmann B, Moldenhauer G, Momburg F: Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high grade malignancy. Int J Cancer 1917; 40:32-39.
11. Becker JC, Brocker EB: Lymphocyte-melanoma interaction: role of surface molecules. Recent Results Cancer Res 1995; 139:205-214.
12. Peltenburg LT, Dee R, Schriee PI: Down regulation of HLA class I expression by c-myc in human melanoma is independent of enhancer A. Nucleic Acids Res 1993; 21:1179-1185.
13. Townsend A: Antigen processing. A new presentation pathway? Nature 1992; 356:386-387.
14. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA: Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177:265-272.
15. Restifo NP, Spiess PJ, Karp SE, Mule JJ, Rosenberg SA: A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992; 175:1423-1431.
16. von Stamm U, Brocker EB, von Depka Prondzinski M, Ruiter DJ, Rumke P, Broding C: Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. Melanoma Res 1993; 3:173-180.
17. Wang ZG, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S: Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frame-shift in beta 2-microglobulin messenger RNA. J Clin Invest 1993; 91:684-692.
18. 2-microglobulin gene expression. J Invest Dermatol 1991; 87:284-292.
19. Karre K, Ljunggren HG: In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 1990; 11:237-244.
20. Diehl M, Munz C, Keilholz W, Stevanovic S, Holmes N, Loke YW: Nonclassical HLA-G molecules are classical peptide presenters. Curr Biol 1996; 6:305-314.
21. Munz C, Holmes N, King A, Loke YW, Colonna M, Schild H: Human histocompatibility leukocyte antigen (HLA)-G molecules inhibit NKAT3 expressing natural killer cells. J Exp Med 1997; 185:385-391.
22. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R: A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248:220-223.
23. Pena J, Alonso C, Solano R, Serrano R, Carracedo J, Ramirez R: Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur J Immunol 1990; 20:2445-2448.
24. Piontek GE, Taniguchi K, Ljunggren HG, Gronberg A, Kiessling R, Klein G: YAC-1 MHC class I variants reveal an association between decreased NK sensitivity and increased H-2 expression after interferon treatment or in vivo passage. J Immunol 1985; 135:4281-4288.
25. Sawada Y, Fohring B, Sheuk TE, Reska K: Tumorigenicity of adenovirus-transformed cells: region E1A of adenovirus 12 confers resistance to natural killer cells. Virology 1985; 147:413-421.
26. Biassoni R, Cantoni C, Falco M, Verdiani S, Bottino C, Vitale M: The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 1996; 183:645-650.
27. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC: Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol 1996; 14:619-648.
28. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activites and secreated proteins. J Immunol 1986; 136:2348-2357.
29. Mosmann TR, Moore KW: The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991; 12:A49-A53.
30. Wegmann TG, Lin H, Guilbert L, Mosmann TR: Bidirectional cytokine interactions in the meternal-fetal relationship: Is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14:353-356.
31. Varner MW: Autoimmune disorders andpregnancy. Semin Perinatol 1991; 15:238-250.
32. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG: Synthesis of T helper 2-type cytokines at the maternalfetal interface. J Immunol 1993; 151:4562-4573.
33. Matthiesen L, Berg G, Ernerudh J, Skogh T: Lymphocyte subsets and auto-antibodies in pregnancies complicated by placental disorders. Am J Reprod Immunol 1995; 33:31-39.
34. Peltz G: A role for CD4+ T-cell subsets producing a selective pettern of lymphokines in the pathogenesis of human chronic inflammatory and allergic diseases. Immunol Rev 1991; 123:23-35.
35. Pellagrini P, Berghella AM, Del Beato T, Cicia S, Adorno D, Casciani CU: Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patiens and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996; 42:1-8.
36. Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP: Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol 1996; 105:344-352.
37. Goodwin JS, Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol 1983; 3:295-315.
38. 2-mediated immunosuppression by first trimester human decidual cells blocks activation of maternal leukocytes in the decidua with potential anti-trophoblast activity. Cell 1989; 120:61-74.
39. Parhar RS, Kennedy TG, Lala PK: Suppression of lymphocyte alloreactivity by early gestational human decidua. I. Characterization of suppressor cells and suppressor molecules. Cell Immunol 1988; 116:392-410.
40. Lala PK, Kennedy TG, Parhar RS: Suppression of lymphocyte alloreactivity by early gestational human decidua. II. Characterization of the suppressor mechanisms. Cell Immunol 1988; 116:411-422.
41. Heyborne K, Silver R: Immunology of postimplantation pregnancy. In Reproductive Immunology, RA Bronson, NJ Alexander, D Anderson, DW Branch, WH Kutteh (eds). Cambridge, MA, Blackwell, 1996, p 401.
42. Klein DC, Raisl LG: Prostaglandins: stimulation of bone resorption in tissue culture. Endocrinology 1970; 86:1436-1440.
43. Husby G, Strickland RG, Rigler GL, Peake GT, Williams RC Jr: Direct immunochemical detection of prostaglandinE and cyclic nucleotides in human malignant tumors. Cancer 1977; 40:1629-1642.
44. Cummings KB, Robertson RP: Prostaglandin: increases production by renall cell carcinoma. J Urol 1977; 118:720-730.
45. Owen K, Gomolka D, Droller MJ: Lymphocyte-induced production of prostaglandin E2 by tumor cells in vitro: Requirements for direct contact and lymphocyte viability. Cell Immunol 1980; 55:428-435.
46. Plescia OJ, Racis S: Prostaglandins as physiological immunoregulators. Prog Allergy 1988; 44:153-171.
47. Koster FT, Williams JC, Goodwin JS: Cellular immunity in Q fever: modulation of responsiveness by a suppressor T cell-monocyte circuit. J Immunol 1985; 135:1067-1072.
48. Sporn MB, Roberts AB: The transforming growth factor-betas: past, present and future. Ann NY Sci 1990; 593:1-6.
49. Krummel TM, Michna BA, Thomas BL, Sporn MB, Nelson JM, Salzberg AM: Transforming growth factor beta (TGF- beta) induces fibrosis in a fetal wound model. J Pediatr Surg 1988; 23:647-652.
50. Masui T, Wakefield L, Lechner J, LeVeck MA, Sporn MB, Harris CC: Type-beta transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc Natl Sci USA 1986; 83:2438-2442.
51. DeBenedetti F, Falk LA, Ellingsworth LR, Ruscetti FW, Faltynek CR: Synergy between transforming growth factorbeta and tumor necrosis factor-alpha in the induction of monocytic differentitation of human leukemic cell lines. Blood 1990; 75:626-632.
52. Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast RC Jr, Boyer CM: The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol 1990; 75:255-262.
53. Dungy LJ, Siddiqi TA, Khan S: Transforming growth factor-beta 1 expression during placental development. Am J Obstet Gynecol 1991; 165:853-857.
54. Pijnenborg R, Bland JM, Robertson WB, Dixon G, Brosens I: The pattern of interstitial trophoblastic invasion of the myometrium in early human pregnancy. Placenta 1981; 2:303-316.
55. Massague J: The transforming growth factor-beta family. Annu Rev Cell Biol 1990; 6:597-641.
56. Filmus J, Kerbel RS: Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression. Curr Opin Oncol 1993; 5:123-129.
57. Massague J: Receptors for the TGF-beta family. Cell 1992; 69:1067-1070.
58. Geiser AG, Burmester JK, Webbink R, Roberts AB, Sporn MB: Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. J Biol Chem 1992, 267:2588-2593.
59. Moses HL, Yang EY, Pietenpol JA: TGF-beta stimulation and inhibition of cell proliferation: New mechanistic insights. Cell 1990; 63:245-247.
60. Pietenpol JA, Holt JT, Stein RW, Moses HL: Transforming growth factor-beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. Proc Natl Acad Sci USA 1990; 87:3758-3762.
61. Weinberg, RA: Tumor suppressor genes. Science 1991; 254:1138-1146.
62. Hamel PA, Gill RM, Phillips RA, Gallie BL: Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by the product of the RB1 gene. Mol Cell Biol 1992; 12:3431-3438.
63. Weintraub SJ, Prater CA, Dean DC: Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992; 358:259-261.
64. Faulk WP, McIntyre JA: Trophoblast survival. Transplantation 1981; 32:1-5.
65. Coulam CB, Faulk WP, McIntyre JA: Immunotherapy for recurrent spontaneous abortion and its analogies to treatment for cancer. Am J Reprod Immunol 1991; 25:114-119.
66. Torry DS, Faulk WP, McIntyre JA: Regulation of immunity to extraembryonic antigens in human pregnancy. Am J Reprod Immunol 1989; 21:76-81.
67. Johnson PM, Brown PJ: Fc gamma receptors in the human placenta. Placenta 1981; 2:355-370.
68. Suciu-Foca N, Reemtsma K, King DW: The significance of the idiotypic anti-idiotypic network in humans. Transplant Proc 1986; 18:230-234.
69. Torry DS, Faulk WP, McIntyre JA: Trophoblast immunity in human pregnancy defined by anti-idiotype. Am J Reprod Immunol 1991; 25:181-184.
70. Coulam CB, Krysa L, Stern JJ, Bustillo M: Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Am J Reprod Immunol 1995; 34:333-337.
71. Bussel JB, Kimberly RP, Innman RD, Schulman I, Cunningham-Rundles C, Cheung N: Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983; 62:480-486.
72. Roux KH, Tankersley DL: A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990; 144:1387-1395.
73. Gerlyn D, Koprowski H: Anti-idiotypic antibodies in cancer therapy. In Elicitation and Use of Anti-idiotypic Antibodies and Their Biological Applications, C Bona (ed). Boca Raton, FL, CRC Press, 1988, p 123.
74. Wettendorff M, Koprowski H, Herlyn D: Modulation of anti-tumor immunity with anti-idiotypic antibodies. In Idiotypic Network and Diseases, J Cerny, J Hiernaux (eds). Washington, DC, American Society for Microbiology, 1990, p 203.
75. Jerne NK: Towards a network theory of the immune system. Ann Immunol 1974; 125C:373-389.
76. Herlyn D, Somasundaram R, Li W, Maruyama H: Antiidiotype cancer vaccines: past and future. Cancer Immunol Immunother 1996; 43:65-76.
77. Herlyn D, Ross AH, Koprowski H: Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 1986; 232:100-102.
78. Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U: Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA 1987; 84:8055-8059.
79. Herlyn D, Benden A, Kane M, Somasundaram R, Zaloudik J, Sperlagh M: Anti-idiotype cancer vaccines: pre-clinical and clinical studies. In Vivo 1991; 5:615-623.